Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study
Diseases of the Esophagus · 02.03.2026 · 39 (2)
DOI: 10.1093/dote/doag040 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diseases of the Esophagus, online erschienen am 27.04.2026. Verfasst von Maxime E Sanders und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Lymphatic Metastasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Program of Province TCM Sci-Tech Plan, Shanghai Natural Science Foundation.
Abstract (Originalsprache)
Cervical lymph node metastasis in thoracic esophageal cancer occupies a conceptual border zone between locoregional and distant disease. Evidence guiding treatment selection in this population remains limited in Western cohorts. The objective was to evaluate treatment strategies and overall survival outcomes for patients with resectable esophageal cancer and concurrent cervical lymph node metastasis in the Netherlands. This population-based cohort study used the Netherlands Cancer Registry to identify patients with resectable thoracic esophageal or gastroesophageal junction cancer and concurrent cervical lymph node metastasis. Treatment strategies included definitive chemoradiotherapy, neoadjuvant therapy followed by surgery, chemotherapy with or without limited radiotherapy (≤30 Gy), palliative radiotherapy, and best supportive care. Kaplan–Meier analysis and Cox regression adjusted with inverse probability of treatment weighting (IPTW) were used to assess overall survival and treatment effects. Between 2015 and 2021, 412 eligible patients were identified. Median overall survival was 24 months for patients treated with neoadjuvant therapy followed by surgery, 18 months for definitive chemoradiotherapy, 15 months for chemotherapy, 7 months for radiotherapy alone, and 3 months for best supportive care. In multivariable analysis, neoadjuvant therapy followed by surgery was associated with longer survival compared with definitive chemoradiotherapy (HR 0.56 [0.34–0.91]). Similar estimates were observed after IPTW. Higher cN stage and poorer performance status were independently associated with worse survival. Subgroup analysis of neoadjuvant chemoradiotherapy versus chemotherapy within the surgical cohort showed no significant survival difference. In this nationwide cohort, management of thoracic esophageal cancer with concurrent cervical lymph node metastasis was highly heterogeneous. Although neoadjuvant therapy followed by surgery was associated with longer survival, interpretation is limited by baseline differences and potential residual confounding. These findings suggest that surgery may be considered within a multimodality strategy in carefully selected patients and warrant prospective evaluation to better define its role.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
- Department of Medical Oncology, Erasmus Medical Center, Rotterdam, South Holland, The Netherlands.
- Department of Surgery, Erasmus Medical Center, Rotterdam, South Holland, The Netherlands.
ORCID-Profile: Maxime E Sanders, Nadia Haj Mohammad, Bianca Mostert, Bas P L Wijnhoven, Mark I van Berge Henegouwen, Misha D P Luyer, Richard van Hillegersberg
Förderung
- Zhejiang Provincial Natural Science Foundation of China
- Program of Province TCM Sci-Tech Plan
- Shanghai Natural Science Foundation
Zitieren
APA
Sanders, M. E., van der Horst, S., Weijs, T. J., Freund, J. E., Mook, S., Mohammad, N. H., Mostert, B., Wijnhoven, B. P. L., Nieuwenhuijzen, G. A. P., van Laarhoven, H. W. M., van Berge Henegouwen, M. I., Luyer, M. D. P., van der Sluis, P. C., Verhoeven, R. H. A., Lagarde, S. M., Gisbertz, S. S., Ruurda, J. P., & van Hillegersberg, R. (2026). Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study. Diseases of the Esophagus, 39(2). https://doi.org/10.1093/dote/doag040
Vancouver
Sanders ME, van der Horst S, Weijs TJ, Freund JE, Mook S, Mohammad NH, et al. Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study. Diseases of the Esophagus. 2026;39(2). doi:10.1093/dote/doag040
BibTeX
@article{Sanders2026,
author = {Sanders, Maxime E and van der Horst, Sylvia and Weijs, Teus J and Freund, Jan Erik and Mook, Stella and Mohammad, Nadia Haj and Mostert, Bianca and Wijnhoven, Bas P L and Nieuwenhuijzen, Grard A P and van Laarhoven, Hanneke W M and van Berge Henegouwen, Mark I and Luyer, Misha D P and van der Sluis, Pieter C and Verhoeven, Rob H A and Lagarde, Sjoerd M and Gisbertz, Suzanne S and Ruurda, Jelle P and van Hillegersberg, Richard},
title = {Treatment strategies of esophageal cancer with concurrent cervical node metastasis: a Dutch nationwide population-based cohort study},
journal = {Diseases of the Esophagus},
year = {2026},
volume = {39},
number = {2},
doi = {10.1093/dote/doag040}
}
EUVIMED